Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.

Autor: Daher S; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel. Electronic address: s_daher@rambam.health.gov.il., Zer A; Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah Tikva 49100, Israel., Tschernichovsky R; Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah Tikva 49100, Israel., Yacobi R; Institute of Pathology, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel., Barshack I; Institute of Pathology, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel., Tsabari S; Department of Oncology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, 91120, Israel., Rottenberg Y; Department of Oncology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, 91120, Israel., Zick A; Department of Oncology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, 91120, Israel., Gottfried T; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel., Lobachov A; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel., Marom EM; Radiology Department, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel; Tel Aviv University School of Medicine, Tel Aviv 69978, Israel., Urban D; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel; Tel Aviv University School of Medicine, Tel Aviv 69978, Israel., Saad A; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel; Tel Aviv University School of Medicine, Tel Aviv 69978, Israel., Gantz-Sorotsky H; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel., Onn A; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel., Bar J; Thoracic Cancer Unit, Cancer Center, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel; Tel Aviv University School of Medicine, Tel Aviv 69978, Israel.
Jazyk: angličtina
Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2023 Apr; Vol. 178, pp. 229-236. Date of Electronic Publication: 2023 Mar 02.
DOI: 10.1016/j.lungcan.2023.02.023
Abstrakt: Objectives: The identification and targeting of actionable genomic alterations (AGA) have revolutionized the treatment of cancer in general and mostly for non-small cell lung cancer (NSCLC). We investigated whether in NSCLC patients PIK3CA mutations are actionable.
Materials and Methods: Chart review was performed of advanced NSCLC patients. PIK3CA mutated patients were analyzed as two groups: Group A: without any non-PIK3CA established AGA; Group B: with coexisting AGA. Group A was compared to a cohort of non-PIK3CA patients (group C), using t-test and chi-square. To evaluate the impact of PIK3CA mutation on outcome, we compared Group A survival to age/sex/histology matched cohort of non-PIK3CA mutated patients (group D) by Kaplan-Meier method. A patient with a PIK3CA mutation was treated with a PI3Ka-isoform selective inhibitor BYL719 (Alpelisib).
Results: Of a cohort of 1377 patients, 57 are PIK3CA mutated (4.1%). Group A: n-22, group B: n-35. Group A median age is 76 years, 16 (72.7%) men, 10 (45.5%) squamous, 4 (18.2%) never smokers. Two never-smoker female adenocarcinoma patients had solitary PIK3CA mutation. One of them was treated with a PI3Ka-isoform selective inhibitor BYL719 (Alpelisib), with rapid clinical and partial radiological improvement. Group B, compared with Group A, included younger patients (p = 0.030), more females (p = 0.028) and more adenocarcinoma cases (p < 0.001). Compared to group C, group A patients were older (p = 0.030) and had more squamous histology (p = 0.011).
Conclusion: In a small minority of NSCLC patients with PIK3CA mutation there are no additional AGA. PIK3CA mutations may be actionable in these cases.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: